Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 72 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Ag...
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 72 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
DATES:
Approval is withdrawn as of October 23, 2025.
FOR FURTHER INFORMATION CONTACT:
Martha Nguyen, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1676, Silver Spring, MD 20993-0002, 301-796-3471,
Martha.Nguyen@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
The applicants listed in table 1 have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing.
( printed page 45943)
Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.
Stason Pharmaceuticals, Inc., U.S. Agent for Kenton Chemicals and Pharmaceuticals Corp., 11 Morgan, Irvine, CA 92618.
ANDA 074941
Diltiazem HCl injectable, 5 mg/mL
Hospira, Inc.
ANDA 074993
Ketorolac Tromethamine injectable, 30 mg/mL, and 15 mg/mL
Do.
ANDA 075505
Loratadine syrup, 1 mg/mL
Teva Pharmaceuticals USA, Inc., 400 Interpace Parkway, Building A, Parsippany, NJ 07054.
ANDA 075940
Dacarbazine injectable, 200 mg/vial
Hospira, Inc.
ANDA 075962
Tramadol HCl tablet, 50 mg
Watson Laboratories, Inc. (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.), 400 Interpace Parkway, Building A, Parsippany, NJ 07054.
ANDA 076715
Modafinil tablets, 100 mg, and 200 mg
Do.
ANDA 076774
Haloperidol injectable, EQ 5 mg base/mL
Syneos Health, LLC, U.S. Agent for Gland Pharma Limited, 1030 Sync St., Morrisville, NC 27560.
ANDA 078024
Ciprofloxacin in Dextrose, injectable, 5% in plastic container, 200 mg/100 mL, and 400 mg/200 mL
Baxter Healthcare Corp., One Baxter Parkway, Deerfield, IL 60015.
ANDA 078030
Stavudine for solution, 1 mg/mL
Cipla USA, Inc., U.S. Agent for Cipla Limited, 10 Independence Blvd., Suite 300, Warren, NJ 07059.
ANDA 078062
Ciprofloxacin injectable, 200 mg/20 mL (10 mg/mL), and 400 mg/40mL (10 mg/mL)
Baxter Healthcare Corp.
ANDA 078084
Metronidazole in plastic container, injectable, 500 mg/100 mL
Actavis Laboratories FL, Inc., an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc., 400 Interpace Parkway, Building A, Parsippany, NJ 07054.
ANDA 091152
Benztropine Mesylate injectable, 1 mg/mL
Luitpold Pharmaceuticals, Inc., One Luitpold Dr., P.O. Box 9001, Shirley, NY 11967.
ANDA 091397
Levofloxacin injectable, EQ 250 mg/50 mL (EQ 5 mg/mL), EQ 750 mg/150 mL (EQ 5 mg/mL), and EQ 500 mg/100 mL (EQ 5 mg/mL)
Baxter Healthcare Corp.
ANDA 091596
Tranexamic Acid injectable, 100 mg/mL
Fresenius Kabi USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047.
Long Grove Pharmaceuticals LLC, 9450 W Bryn Mawr Ave., Suite 200, Rosemont, IL 60018.
Therefore, approval of the applications listed in table 1, and all amendments and supplements thereto, is hereby withdrawn as of October 23, 2025. Approval of each entire application is withdrawn, including any strengths and dosage forms inadvertently missing from table 1. Introduction or delivery for introduction into interstate commerce of products listed in table 1 without an approved new drug application or ANDA violates sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)). Drug products that are listed in table 1 that are in inventory on October 23, 2025 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
Use this for formal legal and research references to the published document.
90 FR 45942
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Elite Laboratories, Inc., et al.; Withdrawal of Approval of 72 Abbreviated New Drug Applications,” thefederalregister.org (September 24, 2025), https://thefederalregister.org/documents/2025-18453/elite-laboratories-inc-et-al-withdrawal-of-approval-of-72-abbreviated-new-drug-applications.